Biophytis Announces Transfer of ADSs to OTC Market

   Biophytis / Key word(s): Miscellaneous
   Biophytis Announces Transfer of ADSs to OTC Market
   24-Apr-2024 / 23:00 CET/CEST
     ____________________________________________________________

   
   Biophytis Announces Transfer of ADSs to OTC Market

     * ADSs delisted from Nasdaq, which will result in meaningful
       savings
     * ADSs transferred to OTC Pink market; Company will apply to
       trade on OTCQB market
     * Biophytis remains listed on Euronext Growth Paris as its
       primary trading market

   Paris (France) and Cambridge (Massachusetts, USA), April 24, 2024
   - 11:00pm CET - Biophytis SA (Euronext Growth Paris : ALBPS),
   ("Biophytis" or the "Company"), a clinical-stage biotechnology
   company specializing in the  development of  therapeutics for
   age-related diseases, today annouced that on April 24, 2024, the
   Company received formal notice from The Nasdaq Stock Market LLC
   ("Nasdaq") that the Nasdaq Hearings Panel (the "Panel") had
   determined to delist the Company's American Depositary Shares
   ("ADSs") from The Nasdaq Capital Market based upon the Company's
   non-compliance with the stockholders' equity requirement set
   forth in Nasdaq Listing Rule 5550(b). As a result of the Panel's
   decision, Nasdaq will suspend trading in the Company's ADSs
   effective with the opening of business on Friday, April 26, 2024,
   and file a Form 25 with the Securities and Exchange Commission
   (the "SEC") to effect the formal delisting of the Company's ADSs
   from The Nasdaq Capital Market once all applicable Nasdaq appeal
   and review periods have expired.

   The Company anticipates that, concurrent with the suspension of
   trading of its ADSs on Nasdaq, the Company's ADSs will begin
   trading on the OTC Markets' OTC Pink Current Information tier
   under the current symbol "BPTS" while it applies to trade on the
   higher-tier OTCQB market. The Company expects that this transfer
   will meaningfully reduce its ongoing costs of being a
   publicly-traded company.

   The Company's ordinary shares remain listed on Euronext Growth
   Paris as the primary trading market and the Company intends to
   continue its public disclosures in compliance with applicable
   French financial market regulations.

About BIOPHYTIS

   Biophytis SA is a clinical-stage biotechnology company
   specializing in the development of drug candidates for
   age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug
   candidate, is a small molecule in development for muscular
   (sarcopenia, phase 3 ready and Duchenne muscular dystrophy),
   respiratory (Covid-19 phase 2-3 completed) and metabolic diseases
   (obesity, phase 2 to be started). The company is based in Paris,
   France, and Cambridge, Massachusetts. The Company's ordinary
   shares are listed on Euronext Growth (Ticker: ALBPS -ISIN:
   FR0012816825) and the ADSs (American Depositary Shares) are
   listed on Nasdaq Capital Market (Ticker BPTS - ISIN:
   US09076G1040). For more information, visit www.biophytis.com

Disclaimer

   This press release contains forward-looking statements.
   Forward-looking statements include all statements that are not
   historical facts. In some cases, you can identify these
   forward-looking statements by the use of words such as
   "outlook,"  "believes,"  "expects,"  "potential,"  "continues,"
   "may,"  "will,"  "should,"  "could,"   "seeks," "predicts,"
   "intends," "trends," "plans," "estimates," "anticipates" or the
   negative version of these   words or other comparable words. Such
   forward-looking statements are based on assumptions that
   Biophytis considers to be reasonable.  However, there can be no
   assurance that the statements contained in such forward-looking
   statements will be verified, which are subject to various risks
   and uncertainties. The forward- looking statements contained in
   this press release are also subject to risks not yet known to
   Biophytis or not currently considered material by Biophytis.
   Accordingly, there are or will be important factors that could
   cause actual outcomes or results to differ materially from those
   indicated in these statements. Please also refer to the "Risk and
   uncertainties the Company is to face» section from the Company's
   2023 Financial  Report available on BIOPHYTIS website
   (www.biophytis.com) and as exposed in the "Risk Factors" section
   of form 20-F as well as other forms filed with the SEC
   (Securities and Exchange Commission, USA). We undertake no
   obligation to publicly update or review any forward-looking
   statement, whether as a result of new information,  future
   developments or otherwise, except as required by law.

Biophytis contacts


Investor relations

Nicolas Fellmann, CFO

Investors@biophytis.com


Media

Antoine Denry: antoine.denry@taddeo.fr - +33 6 18 07 83 27

Nizar Berrada: nizar.berrada@taddeo.fr - +33 6 38 31 90 50

____________________________________________________________

   Dissemination of a Financial Wire News, transmitted by EQS Group.
   The issuer is solely responsible for the content of this
   announcement.
     ____________________________________________________________

   Language:    English
   Issuer:      Biophytis
                14 avenue de l´Opéra
                75001 Paris
                France
   Internet:    https://www.biophytis.com
   ISIN:        US09076G1040, FR0012816825
   EQS News ID: 1888841

   End of Announcement - EQS News Service
     ____________________________________________________________

1888841 24-Apr-2024 CET/CEST